Sun Pharma completes Ranbaxy deal4 min read . Updated: 26 Mar 2015, 12:16 AM IST
Deal's closure comes after the receipt of multiple approvals; Ranbaxy shares will stop trading on 6 April
Mumbai: Sun Pharmaceutical Industries Ltd, India’s most valuable drug maker, has completed the $3.2 billion acquisition of Ranbaxy Laboratories Ltd after almost a year of navigating the regulatory gauntlet to create the world’s fifth-biggest generic pharmaceutical company by revenue.
Select your Category